Dr. Borchmann on Next Steps With Tisagenlecleucel in DLBCL

Peter Borchmann, MD
Published: Monday, Sep 10, 2018



Peter Borchmann, MD, professor, University Hospital of Cologne, Cologne, Germany, discusses next steps with tisagenlecleucel (Kymriah) in diffuse large B-cell lymphoma (DLBCL).

In findings from the phase II JULIET study, the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel showed an objective response rate of 52% in adult patients with relapsed/refractory DLBCL. Following these encouraging results, Borchmann says that physicians would like to see tisagenlecleucel moved to earlier lines of therapy.

This is a very difficult-to-treat patient population, Borchmann says, and outcomes for second-line treatment for patients are very poor, regardless of transplant eligibility status. A randomized phase III trial has been planned to compare tisagenlecleucel to second-line standard of care. This trial will be very important, Borchmann says, because efficacy for high-dose chemotherapy and transplantation is low, and toxicities are high.
SELECTED
LANGUAGE


Peter Borchmann, MD, professor, University Hospital of Cologne, Cologne, Germany, discusses next steps with tisagenlecleucel (Kymriah) in diffuse large B-cell lymphoma (DLBCL).

In findings from the phase II JULIET study, the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel showed an objective response rate of 52% in adult patients with relapsed/refractory DLBCL. Following these encouraging results, Borchmann says that physicians would like to see tisagenlecleucel moved to earlier lines of therapy.

This is a very difficult-to-treat patient population, Borchmann says, and outcomes for second-line treatment for patients are very poor, regardless of transplant eligibility status. A randomized phase III trial has been planned to compare tisagenlecleucel to second-line standard of care. This trial will be very important, Borchmann says, because efficacy for high-dose chemotherapy and transplantation is low, and toxicities are high.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x